MUMBAI, India, June 24 -- Intellectual Property India has published a patent application (202617060133 A) filed by Synapse Research Institute on May 12, 2026, for Molecules For Reversing Anti-Coagulant Activity Of Direct Oral Anticoagulants.
Inventors include De Laat, Henricus Bastiaan; and Roest, Mark.
The application for the patent was published on June 12, 2026, under issue no. 24/2026.
Abstract: The present invention relates to binding molecules capable of reversing the anti-coagulant activity of direct oral anticoagulants in-vivo and in-vitro. The present invention, more particularly concerns binding molecules for reversing the factor Xa inhibition activity of a factor Xa inhibitor such as in a patient to whom a factor Xa inhibitor is administered. The present invention is further related to binding molecules capable of reversing the anti-coagulant activity of direct oral anticoagulants, for use in medicine and diagnostics. More particularly, the present invention concerns binding molecules for use in the treatment or prevention of bleeding, and for use in the detection and quantification of such molecules, e.g. in human plasma. The present invention further provides a method for detecting a factor Xa inhibitor in a sample.
Disclaimer: Curated by HT Syndication.
